The use of SGLT2 inhibitors vs DDP-4 inhibitors is associated with a reduced risk of developing different types of dementia.
Besides stomach cancer, the FDA also raised a similar concern for PD-1 drugs in first-line esophageal squamous cell carcinoma ...
In just two neutron experiments, scientists discovered remarkable details about the function of an enzyme that can aid drug ...
If approved, the potential restrictions would impact Merck’s Keytruda and Bristol Myers Squibb’s Opdivo, which are marketed ...
ZORYVE demonstrated consistent efficacy in disease clearance and reduction in itch for individuals with atopic dermatitis (AD) regardless of ...
The hope is that the two drugs could be combined with new KRAS inhibitor drugs from Amgen and Mirati to improve their efficacy, as well as potentially a dual therapy for other cancers. BridgeBio ...
Expert Rev Clin Pharmacol. 2013;6(3):323-332.
The Italian firm aims to bring its lead candidate, Aptadir Ce-49, into clinical trials for myelodysplastic syndrome next year.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback